What is the next earnings date for PMCB stock?
PHARMACYTE BIOTECH INC (PMCB) will report earnings on 2026-08-10.
PHARMACYTE BIOTECH INC (PMCB) Forecast, Price Target & Analyst Ratings
NASDAQ:PMCB • US71715X2036
Current stock price
0.69 USD
-0.01 (-1.57%)
At close:
0.7207 USD
+0.03 (+4.45%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHARMACYTE BIOTECH INC (PMCB).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.69 to mean target of N/A, Based on 6 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
PMCB was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about PMCB.
In the previous month the buy percentage consensus was at a similar level.
PMCB was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-11-08 | HC Wainwright & Co. | Initiate | Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 10, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | ||||||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.26M | -6.07M 54.22% | -4.44M 26.85% | -6.98M -57.21% | -4.1M 41.26% | -3.83M 6.59% | -3.63M 5.22% | -4.39M -20.94% | -6.46M -47.15% | -6.52M -0.93% | -4.378M 32.85% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
PHARMACYTE BIOTECH INC / PMCB Forecast FAQ
What is the consensus rating for PMCB stock?
The consensus rating for PHARMACYTE BIOTECH INC (PMCB) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.